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Abstract Methyl-L-cyclodextrin (MLCD) was used to explore
a role for cholesterol-enriched plasma membrane microdomains
in coupling lysophosphatidic acid (LPA) stimulation to phos-
phoinositide 3-kinase (PI3K) activation. Cholesterol depletion
strongly inhibited the production of phosphatidylinositol 3,4-bis-
phosphate and phosphatidylinositol 3,4,5-trisphosphate in Vero
cells stimulated with LPA. In agreement, the phosphorylation of
Akt/protein kinase B, but not of Erk kinases, was suppressed by
MLCD. MLCD did not interfere with the overall phospholipid
metabolism, and its e¡ects were reversed in cholesterol add-back
experiments. Finally, PI3K was detected in lipid rafts prepared
from control but not MLCD-treated cells, suggesting that these
microdomains contribute to LPA signalling by compartmental-
ising component(s) of the PI3K pathway.
. 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Lysophosphatidic acid (LPA), a lipid mediator involved in
various normal and pathophysiological processes, promotes
the proliferation or survival of numerous cell types, like a
peptide growth factor. This biological activity is mediated
by at least three di¡erent G protein-coupled receptors that
can activate several signalling pathways involved in cell
growth control. Besides the so-called Ras/mitogen-activated
protein kinase pathway (MAPK), we and others have shown
that phosphoinositide 3-kinase (PI3K) is an important inter-
mediate of LPA mitogenic activity (review in [1]). PI3K phos-
phorylates the 3P position of the inositol ring of phosphoino-
sitides to produce lipids that are key actors of signalling
pathways. For example, stimulation of ¢broblast cells with
LPA or other mitogens leads to the conversion of phosphati-
dylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to phosphatidyl-
inositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3). This latter mol-
ecule controls the intracellular distribution and/or activation
of signalling proteins involved in cell proliferation or survival,
including the serine/threonine kinase Akt/protein kinase B
(PKB) [2].
From a molecular point of view, two types of PI3Ks can be
activated in response to LPA stimulation. PI3KQ has the
unique biochemical feature to be directly activated by hetero-
trimeric G proteins and was thus initially considered as the
best candidate target of LPA [3]. On the other hand, we have
shown that the PI3KL isoform was important for the mito-
genic activity of LPA in non-haematopoietic cells that do not
express PI3KQ [4,5]. However, the mechanisms coupling LPA
stimulation to PI3KL have to be further de¢ned. Indeed, this
isoform is classically activated downstream of tyrosine kinases
through the recruitment of its associated p85 regulatory sub-
unit to phosphotyrosine-containing motifs. Transactivation of
the epidermal growth factor receptor (EGFR), as well as G
protein LQ subunits, is thought to play an important role in
PI3KL activation [6,7], but the molecular determinants of
these processes have remained elusive.
Recently, plasma membrane microdomains have been pro-
posed as initiation platforms for signalling pathways [8]. For
example, detergent-resistant membranes enriched in glyco-
sphingolipids and cholesterol are thought to play an essential
role in T cell receptor activation by concentrating membrane-
associated signalling proteins, thereby facilitating early signal
transduction [9]. These so-called lipid rafts can be isolated
from cell lysates by £otation on sucrose gradient. In epithelial
or mesenchymal cells, lipid rafts called caveolae are charac-
terised by the presence of caveolin, a cholesterol-binding pro-
tein that contains a sca¡olding domain and tyrosine residues
that can bind to a number of signalling molecules, including
the EGFR [10]. Entire signalling modules such as the Ras/
MAPK pathway have been identi¢ed in caveolae, suggesting
that it might be an important compartment for growth factor-
induced mitogenesis [11]. However, a number of recent re-
ports indicate that these structures are in fact modulatory
units for cell responses by sequestering signalling proteins (re-
views in [8,10]). As an illustration of this, targeted downregu-
lation of caveolin-1 in NIH-3T3 cells has been reported to
lead to the hyperactivation of the Ras/MAPK pathway and
to cell transformation [12].
Nevertheless, the dynamic properties of lipid rafts suggested
that they might be important centres of early signalling pro-
cesses. Because the mechanisms underlying PI3K activation
by LPA in non-haematopoietic cells remain poorly under-
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stood, we have explored whether lipid rafts could participate
in this process.
2. Materials and methods
2.1. Materials
LPA and monoclonal anti-phosphoErk antibody were from Sigma.
Polyclonal antibodies against phosphoAkt/PKB (Ser473) and against
p85 were from Cell Signaling and Upstate Biotechnology, respectively.
Monoclonal anti-caveolin antibody was from Transduction Labora-
tory. Cell culture reagents were from Life Technologies.
2.2. Cell culture and stimulation
Vero cells (ATCC CCL 81) were maintained in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 7.5% foetal bovine se-
rum and antibiotics. For stimulation, subcon£uent cells were incu-
bated overnight in serum-free medium before stimulation with LPA
(10 WM, 5 min).
2.3. Depletion, repletion and assay of cellular cholesterol
To remove cholesterol, serum-starved cells were incubated in
DMEM containing the indicated concentration of methyl-L-cyclodex-
trin (MLCD) (Sigma) for 1 h at 37‡C. For cholesterol repletion, de-
pleted cells were incubated with a solution containing 0.2 mM of
preformed MLCD/cholesterol (10:1 mol/mol) complexes, similar to
a previously described procedure [13]. To assay the cholesterol cell
content, cellular lipids were extracted by the method of Bligh and
Dyer [14] in the presence of 15 Wg stigmasterol (Sigma) as an internal
standard, then injected into a gas chromatograph, as previously de-
scribed [15].
2.4. Phospholipid analysis
Cells grown in 10-cm plates were serum-starved for 24 h upon
reaching 80^90% con£uence, then labelled for 5 h with 0.2 mCi of
[32P]H3PO4 (Amersham) per ml in phosphate-free DMEM (Sigma).
Cells were then processed or not for cholesterol depletion/repletion as
indicated, followed by lipid extraction as previously described [7].
Lipid extracts were resolved by thin layer chromatography (TLC).
For analysis of PI3K lipid products, the area corresponding to poly-
phosphoinositides was scraped o¡, deacylated by 20% methylamine
and analysed by high performance liquid chromatography (HPLC)
[7].
2.5. Immunoblotting procedures
For immunoblotting analysis of cell lysates, cells were directly
scraped o¡ in electrophoresis sample bu¡er, then boiled and processed
for immunoblotting using standard procedures. Blots were developed
using chemiluminescence (Amersham Pharmacia Biotech).
2.6. Raft isolation
This procedure was performed essentially as described [16]. Brie£y,
cells were scraped in MES-bu¡ered saline (MBS: 25 mM MES pH
6.5, 150 mM NaCl) supplemented with 1% Triton X-100, 2 mM
phenylmethylsulphonyl £uoride and 10 Wg/ml each of aprotinin and
leupeptin. Lysates were obtained using a Dounce homogeniser, clari-
¢ed by centrifugation, then adjusted to 40% sucrose and placed at the
bottom of an ultracentrifuge tube. A step sucrose gradient (5, 10, 15,
20, 25, 30%) in MBS was then layered on top. Samples were then
centrifuged for 16 h at 34 000Ug. Fractions of 1 ml were collected,
diluted 1/1 in MBS, then subjected to a 14 000Ug centrifugation for
30 min. Pellets were resuspended and boiled in electrophoresis sample
bu¡er, then processed for immunoblotting analysis.
3. Results
3.1. Cholesterol level speci¢cally modulates PI3K activation in
response to LPA
To explore the role of rafts in PI3K signalling we used a
non-transformed monkey kidney cell line (Vero) that displays
a strong increase of PI3K lipid products upon LPA stimula-
tion [7]. Because cholesterol is a critical component of deter-
gent-resistant microdomains, we investigated whether treat-
ment with MLCD to remove cell cholesterol would a¡ect
PI3K activation in response to LPA. MLCD is a water-soluble
cyclic saccharide that has been used as a raft-disrupting agent
due to its high capacity for encapsulating cholesterol [17]. As
shown in Fig. 1, treatment of Vero cells with 7.5 mM MLCD
strongly reduced the formation of the two major PI3K lipid
products induced by LPA, i.e. PtdIns(3,4)P2 and PtdIns-
(3,4,5)P3. To determine whether adding back cholesterol to
the cells would relieve this inhibition, depleted cells were fur-
ther incubated with a MLCD/cholesterol mixture described as
a cholesterol repletion solution [13]. As shown in Fig. 1, this
treatment partially restored the production of the two PI3K
lipid products. Taken together, these results suggest that cho-
lesterol depletion in Vero cells interferes with PI3K activation
in response to LPA.
To determine whether cholesterol depletion speci¢cally
modulated the PI3K signalling pathway or exerted an overall
inhibitory e¡ect on LPA signalling, we compared the activa-
tion of Akt/PKB, a downstream e¡ector of PI3K, with that of
the MAPK Erk. This was achieved by studying the phosphor-
ylation status of both kinases in lysates of cells treated with
MLCD and LPA, using immunoblotting with phosphospeci¢c
antibodies. As expected in light of the results in Fig. 1, MLCD
strongly reduced Akt/PKB phosphorylation induced by LPA,
the inhibition being total when the MLCD concentration
reached 7.5 mM. Cholesterol repletion with the MLCD/cho-
lesterol mixture partially relieved this inhibition (Fig. 2A). In
contrast with Akt, Erk phosphorylation induced by LPA was
much less altered by MLCD treatments (20^25% inhibition at
the highest doses of MLCD, Fig. 2B). Moreover, immunoblot-
ting of the p85 subunit of PI3K in lysates from control or
MLCD-treated cells did not reveal any variation in p85
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Fig. 1. Cholesterol level regulates the synthesis of PI3K lipid prod-
ucts induced by LPA. Serum-starved Vero cells were incubated for
5 h with [32P]H3PO4, then stimulated or not with LPA as indicated.
Lipids were then extracted, separated by TLC, and phosphoinositi-
des were further analysed by HPLC. When indicated, cells were sub-
jected before stimulation to cholesterol depletion using 7.5 mM
MLCD (dark grey bars), followed by cholesterol repletion using a
MLCD/cholesterol mixture (light grey bars). Data represent meanQ
S.E.M. from three experiments.
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amounts, thereby excluding a major loss of integrity in cho-
lesterol-depleted cells (Fig. 2A). In addition, because EGFR is
a critical mediator of PI3K activation induced by LPA [7], we
checked that MLCD treatments did not signi¢cantly modify
LPA-induced EGFR phosphorylation, although cholesterol
depletion moderately increased the basal phosphorylation of
EGFR in unstimulated cells (data not shown). Altogether,
these results suggest that cholesterol depletion speci¢cally af-
fects the PI3K pathway, implying a novel positive role for
lipid rafts in LPA signalling.
3.2. MLCD as a tool to manipulate cell cholesterol without
interfering with the overall phospholipid metabolism
Although the above data suggested that cholesterol deple-
tion speci¢cally altered PI3K signalling, it was important to
check that MLCD treatments actually modi¢ed the level of
cellular cholesterol, without interfering with the overall phos-
pholipid metabolism. This was achieved ¢rst by measuring
cholesterol content in control and MLCD-treated cells using
gas chromatography. As shown in Fig. 3A, a 1 h treatment
with MLCD dose-dependently removed cholesterol from Vero
cells, the depletion reaching over 80% at the concentration of
7.5 mM. Under these conditions, a subsequent incubation
with MLCD/cholesterol complexes restored the cellular cho-
lesterol to nearly 80% of its initial level, thereby validating the
use of MLCD and the MLCD/cholesterol mixture to manip-
ulate cholesterol level. To determine whether these treatments
a¡ected the overall metabolism of phospholipids, cells were
metabolically labelled with [32P]H3PO4 followed by lipid ex-
traction and TLC. Fig. 3B shows that treatment of Vero cells
with MLCD, followed or not by the cholesterol repletion
mixture, did not modify the labelling of major cellular phos-
pholipids, including phosphoinositides. We conclude that
MLCD allows manipulating cholesterol level without signi¢-
cantly interfering with the phospholipid metabolism.
3.3. Cholesterol depletion disrupts lipid rafts and PI3K
localisation
Because cholesterol is an important component of deter-
gent-resistant microdomains, the e¡ect of cholesterol deple-
tion on PI3K activation suggested an essential, yet unknown,
positive role of lipid rafts in this pathway. To begin to explore
this question, Triton X-100-resistant membranes were pre-
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Fig. 2. E¡ect of cholesterol level modulation on LPA-induced phos-
phorylation of Akt and Erk. A: Quiescent Vero cells were treated
for 1 h with the indicated concentration of MLCD, followed by
cholesterol repletion with the MLCD/cholesterol mixture when indi-
cated (MLCD-chol). Cells were then stimulated with LPA, lysed in
SDS^PAGE sample bu¡er and processed for immunoblotting analy-
sis against phosphoAkt (P-Akt), or p85 to control sample prepara-
tion and gel loading. B: Anti-phosphoErk immunoblotting was per-
formed on cells processed as in A. Anti-phosphoAkt and anti-
phosphoErk immunoblots were analysed by densitometry using the
NIHimage software. Data represent meanQS.E.M. from three ex-
periments.
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Fig. 3. Speci¢city of MLCD treatments regarding cellular cholesterol
and phospholipid metabolism. A: Serum-starved Vero cells were
treated for 1 h with the indicated concentration of MLCD followed
by cholesterol repletion using MLCD/cholesterol complexes (MLCD-
chol) when indicated. Cells were then subjected to lipid extraction,
followed by cholesterol assay. B: Cells were incubated with [32P]-
H3PO4, then subjected or not to cholesterol depletion (7.5 mM
MLCD) and repletion as indicated. Lipids were then extracted, sepa-
rated by TLC, revealed with a phosphorimager and identi¢ed with
reference to puri¢ed standards. PtdA, phosphatidic acid; PtdCho,
phosphatidylcholine; PtdEth, phosphatidylethanolamine.
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pared from Vero cells using centrifugation across sucrose gra-
dients. Upon macroscopic observation, a light-refractive band
was clearly visible in the top third of gradients prepared from
control cells (not shown), strongly suggesting the presence of
lipid rafts in these fractions. The di¡erent density fractions
were then collected and analysed by anti-caveolin immuno-
blotting. In agreement with the macroscopic observation, a
large amount of caveolin was detected in fractions 3 and 4
that were thus taken as raft-containing fractions (Fig. 4A).
When cells were treated with 7.5 mM MLCD, the intensity
of the light-refractive band (not shown) and caveolin immu-
nodetection in fractions 3 and 4 were both severely decreased,
then restored by the cholesterol repletion mixture, albeit be-
low its initial level (Fig. 4A). These results con¢rmed that
cholesterol depletion with MLCD disrupted lipid rafts, there-
fore suggesting that the microdomain integrity is important
for PI3K activation. Nevertheless, it was essential to identify
the presence of PI3K in lipid rafts, which was achieved using
immunoblotting. Fig. 4B shows that p85 can be detected in
rafts from control, but not from cholesterol-depleted cells,
and cholesterol repletion restored the association of p85
with lipid rafts. We propose that the regulation of PI3K ac-
tivity by cholesterol level points to a novel positive function
for lipid rafts in LPA signalling.
4. Discussion
Because the mechanisms coupling LPA stimulation to PI3K
activation remain poorly understood, we searched for a par-
ticipation of detergent-resistant membrane microdomains, pu-
tative regulatory platforms for proximal signalling events. Our
approach was based on the disruption of these microdomains
using the cholesterol-encapsulating drug MLCD, since choles-
terol is an essential backbone component of these structures.
Our assays of cell cholesterol in parallel with phospholipid
analysis showed that MLCD turned out to be a very powerful
tool to manipulate cholesterol level without seemingly inter-
fering with the overall cell content and metabolism of phos-
pholipids. In addition, we veri¢ed that MLCD treatment did
alter the amount of lipid rafts present in Vero cells, which
makes it possible to consider, in these conditions, the choles-
terol content of cells as an indirect marker of microdomain
integrity.
We thus observed that cholesterol level strongly modulated
the activation of PI3K in response to LPA. Indeed, cholester-
ol depletion inhibited both LPA-stimulated synthesis of PI3K
lipid products and Akt/PKB phosphorylation, whereas choles-
terol add-back experiments restored both responses, although
below their initial level. Cell fractionation results suggested
that this partial e¡ect of repletion is due to the conditions
of incubation with MLCD/cholesterol complexes that did
not allow cells to fully recover their initial content in lipid
rafts.
Interestingly, cholesterol depletion was found to abolish
Akt phosphorylation while its inhibitory e¡ect on the synthe-
sis of PI3K lipid products was not total. Still, MLCD had
a strong e¡ect (80% inhibition) on the production of
PtdIns(3,4)P2, a critical molecule for Akt activation [2]. More-
over, the current understanding of Akt activation mechanism
seems compatible with the notion that this kinase could need
a threshold concentration of PI3K lipid products to get acti-
vated. In brief, PI3K lipid products do not directly activate
Akt but induce its membrane translocation and colocalisation
with its upstream activating kinases, the phosphoinositide-de-
pendent kinases (PDKs) that are also controlled by PI3K lipid
products. It thus seems likely that a minimal concentration of
these lipids must be achieved to induce a su⁄cient degree of
‘clustering’ of Akt and the PDKs required for Akt activation.
Regarding the speci¢city of cholesterol depletion on LPA
signalling, we observed that the MAPK pathway was not
strongly a¡ected by MLCD. Indeed, only a moderate inhibi-
tion of Erk phosphorylation was observed at the highest doses
of MLCD, as expected since MAPK activation in response to
LPA is partly dependent on PI3KL in Vero cells [5]. In agree-
ment, cholesterol depletion did not interfere with the LPA-
induced phosphorylation of EGFR (data not shown), a crit-
ical mediator of MAPK and PI3K activation [7]. Conse-
quently, this excluded the possibility that MLCD induced an
overall loss of cell sensitivity to LPA by depleting, together
with cholesterol, important membrane components of the cell
signalling machinery, e.g. LPA receptors. These data rather
suggest that cholesterol depletion speci¢cally a¡ects at least
one component of the PI3K pathway.
Although a positive role for lipid rafts has been clearly
established in lymphocyte signalling [8], these structures ap-
peared to play rather a regulatory role in non-haematopoietic
cells. For example, cholesterol depletion has been reported to
hyperactivate the Ras/MAPK pathway in EGF-stimulated ¢-
broblasts [18], which may be due to EGFR sequestration in
lipid rafts leading to impaired ligand accessibility [19]. In con-
trast, our data suggest that these membrane microdomains are
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Fig. 4. E¡ect of cholesterol depletion on lipid rafts and distribution
of the p85 PI3K subunit. Vero cells were treated without (control)
or with 7.5 mM MLCD, followed by cholesterol repletion with the
MLCD/cholesterol mixture when indicated (MLCD-chol). Cells were
then lysed with 1% Triton X-100, followed by fractionation on su-
crose step gradients. Fractions were collected then analysed by im-
munoblotting anti-caveolin (A) and anti-p85 subunits of PI3K (B).
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an essential site for PI3K activation during LPA stimulation,
implying that lipid rafts also have a positive function in mito-
genic signalling. The fact that cholesterol content speci¢cally
modulates the PI3K pathway suggests that at least one im-
portant component of PI3K signalling is notably compart-
mentalised in lipid rafts. We thus started to explore the local-
isation of p85-dependent PI3Ks, taking into account that
PI3KQ is not expressed in Vero cells [7]. Interestingly, p85
was identi¢ed in lipid rafts and its localisation was modi¢ed
by the di¡erent MLCD treatments. Because the EGFR is also
present in rafts, one may assume that these microdomains
represent a privileged location for interaction between
EGFR and p85. Moreover, studies addressing the intracellular
distribution of the PI3K substrate PtdIns(4,5)P2 have shown
that this lipid is highly concentrated in lipid rafts of di¡erent
human cells [20,21], although the factors that govern this
compartmentalisation remain unknown. Therefore, our results
suggest that, besides sequestering EGFR to limit EGF-in-
duced signalling, lipid rafts play a positive role in LPA signal-
ling by bringing together EGFR, PI3K and PtdIns(4,5)P2,
thereby providing a favourable environment for PI3K activa-
tion.
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